NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

R Shareholders Click Here: https://www.zlk.com/pslra-1/ryder-system-inc-loss-submission-form?prid=7626&wire=1
CLNY Shareholders Click Here: https://www.zlk.com/pslra-1/colony-capital-inc-loss-submission-form?prid=7626&wire=1
CCL Shareholders Click Here: https://www.zlk.com/pslra-1/carnival-corporation-loss-submission-form?prid=7626&wire=1

* ADDITIONAL INFORMATION BELOW *

Ryder System, Inc. (NYSE:R)

R Lawsuit on behalf of: investors who purchased July 23, 2015 – February 13, 2020
Lead Plaintiff Deadline: July 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ryder-system-inc-loss-submission-form?prid=7626&wire=1

According to the filed complaint, during the class period, Ryder System, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Ryder's financial results were inflated as a result of the Company's practice of overstating the residual values of the vehicles in its fleet; (2) there was no reasonable basis to believe that Ryder would sell its used vehicles for the amounts that it had assigned to them; (3) Ryder's residual values for its fleet of vehicles exceeded the expected future values that would be realized upon the sale of those vehicles; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Colony Capital, Inc. (NYSE:CLNY)

CLNY Lawsuit on behalf of: investors who purchased August 9, 2019 – May 7, 2020
Lead Plaintiff Deadline: July 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/colony-capital-inc-loss-submission-form?prid=7626&wire=1

According to the filed complaint, during the class period, Colony Capital, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Colony's sale of its industrial real estate portfolio and the bifurcation of Colony Credit Real Estate's portfolio were foreseeably likely to negatively impact Colony's financial and operating results; (ii) certain of Colony's remaining portfolio companies carried unsustainable levels of debt secured by hotels and healthcare-related properties and were thus at a significant risk of default; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Carnival Corporation & Plc (NYSE:CCL)

CCL Lawsuit on behalf of: investors who purchased September 26, 2019 – May 1, 2020
Lead Plaintiff Deadline: July 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/carnival-corporation-loss-submission-form?prid=7626&wire=1

According to the filed complaint, during the class period, Carnival Corporation & Plc made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's medics were reporting increasing events of COVID-19 illness on the Company's ships; (2) Carnival was violating port of call regulations by concealing the amount and severity of COVID-19 infections on board its ships; (3) in responding to the outbreak of COVID-19, Carnival failed to follow the Company's own health and safety protocols developed in the wake of other communicable disease outbreaks; (4) by continuing to operate, Carnival ships were responsible for continuing to spread COVID-19 at various ports throughout the world; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
http://www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 595591

The coronavirus outbreak has resulted a shortage of diagnostic tools and infrastructure, generating opportunities for players in the chemiluminescence immunoassay (CLIA) analyzer market to bridge the gap between supply and demand. Research funding will support growth throughout the pandemic.

ROCKVILLE, MD / ACCESSWIRE / June 29, 2020 / Owing to the unprecedented spread of the coronavirus pandemic, investments into diagnostics including point of care tests and central laboratory tests are aiding in the development of varied tools including chemiluminescence immunoassay analyzers. Public and private sector funding into the medical sector will help in market growth through and after the crisis period.

The global chemiluminescence immunoassay (CLIA) analyzer market is anticipated to rise at an healthy 6.4% CAGR throughout the period of projection between 2020 and 2025. The Fact.MR study reveals that, despite the potential applications, lack of awareness remains a key obstacle to the CLIA analyzers market.

"Development of analyzers with complex modalities and high-throughput generates key revenue opportunities for players in global chemiluminescence immunoassay analyzers market. The market is gaining demand for informatics along with process analytics to integrate varied functionalities within individual analyzers. These innovations will aid market growth during the pandemic period," says the FACT.MR study.

Request a report sample to gain more market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4734

Chemiluminescence Immunoassay (CLIA) Analyzer Market- Key Takeaways

CLIA reagents will account for substantial market revenue, owing to a high replacement rate.
Oncology applications will generate key remunerative opportunities for the chemiluminescence immunoassay analyzers market.
Hospitals and diagnostic are major end users of CLIA analyzers, owing to wide scope of applications.
North America is a major market for chemiluminescence immunoassay analyzers owing to easy access to new technology and high prevalence of chronic ailments.

Chemiluminescence Immunoassay (CLIA) Analyzer Market- Driving Factors

Rapid rise in the number of chronic diseases including cancer, diabetes, autoimmune ailments, and cardiovascular diseases bolster market growth.
Rise in geriatric population and higher cases of hospitalization generate key growth opportunities.
Rising investments in the healthcare sector contribute to major market developments.
Manufacturer efforts towards research and development activities contribute to market growth.

Chemiluminescence Immunoassay (CLIA) Analyzer Market- Major Restraints

Fragmented nature of the CLIA analyzer market limits profitability for market players.
Lack of awareness about CLIA analyzers, particularly in developing economies hold back market growth.

COVID-19 Impact on Chemiluminescence Immunoassay (CLIA) Analyzer Market

The wide and rapid spread of the coronavirus has generated a high requirement for testing and diagnostic tools and services. With extensive funding in the healthcare sector, developments in the chemiluminescence immunoassays have grown during this period.

CLIA immunoassay analyzers provide quick results and are fairly easy to use. High accuracy rates in comparison to most alternatives is bolstering its popularity. On the other hand, restrictions on transport and international trade will create challenges for market players. However, with uncertainty over the duration of the pandemic, the need for chemiluminescence immunoassay analyzers will remain strong in the months ahead.

Explore the global chemiluminescence immunoassay (CLIA) analyzers market with 76 figures, 63 data tables, along with the table of contents of the report. You can also find detailed segmentation on

https://www.factmr.com/report/4734/chemiluminescence-immunoassay-clia-analyzers-market

Competitive Landscape

The chemiluminescence immunoassay (CLIA) analyzers market is fragmented, with numerous small and medium scale players in the industry. Major players are pushing to strengthen their market presence through acquisitions and product launches. For instance, DiaSorin S.p.A. has announced that its CLIA Liaison analyzer has received emergency use authorization from the FDA for covid-19 tests. Similarly, Siemens Healthcare has also revealed its range of automated CLIA analyzer platform.

F. Hoffmann-La Roche AG, Mindray Medical International Limited, Siemens Healthcare GmbH, Beckman Coulter Inc., and DiaSorin S.p.A are some of the top chemiluminescence immunoassay (CLIA) analyzer manufacturers in the global market.

About the Report

This study offers readers a comprehensive market forecast of the chemiluminescence immunoassay (CLIA) analyzers market. Global, regional and country-level analysis of the top industry trends impacting the chemiluminescence immunoassay (CLIA) analyzers market is covered in this FACT.MR study. The report offers insights on the chemiluminescence immunoassay (CLIA) analyzers market on the basis of application (endocrine disorders, oncology, infectious diseases, hepatitis and retrovirus, cardiovascular disorders, allergy, autoimmunity, drug discovery & development, and others), product (analyzers, reagents, and consumables), and end user (hospitals, clinical laboratories, pharmaceutical & biologicals industries, and others) across five regions (North America, Latin America, Europe, Asia Pacific, and MEA).

Explore FACT.MR's Comprehensive Coverage of Healthcare Landscape

Epigenetics Market– Get the latest insights on the global epigenetics market through FACT.MR's report covering analysis for projection period (2018-2027).

Medical Mask Market– FACT.MR's study on the global medical mask market covers trends, tech advancements, players, and strategies for the course of forecast period (2020-2030).

Dental Amalgamators Market– Obtain analysis on the global dental amalgamators market through FACT.MR's latest report covering competitive analysis, key regions, along with segmental analysis for 2018-2028.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1490/global-chemiluminescence-immunoassay-clia-analyzers-market

SOURCE: Fact.MR

ReleaseID: 595582

Water usage in Egypt is increasing on the back of a procreating population, improvement in living standards and government incentives towards expanding the agricultural and industrial sectors.

DUBAI, UAE / ACCESSWIRE / June 29, 2020 / Egypt is one of the fastest developing countries in terms of economic growth across the Middle East. The agriculture sector consumes the maximum amount of water, corresponding to over four-fifths of the Nile River. The total cultivable land available as of 2016 amounted to 3.8 million hectares. Agriculture contributes over 14% of the country's GDP, with a total income of 256.9 billion Egyptian pounds. Additionally, a rapidly expanding population pool has also augmented water usage for domestic purposes.

Based on these trends, the demand for centrifugal pumps to transport water is increasing. It is anticipated that the Egypt below 30 HP centrifugal water pumps market will reach a valuation of US$ 37.1 Mn by the end of 2020. The sheer simplicity of the pump's design makes it easier to transport water to different areas, making them ideal choices for various end-uses. However, an increasing population also entails greater pressure on existing resources. Egypt's rapidly expanding population is straining water availability, leading to acute shortages. This impediment is anticipated to hinder the market in the long-run.

"Given Egypt's lengthy history of irrigation due to its close proximity to the Nile River, agriculture has always flourished across the country, prompting people to divert water into basins by constructing canals and boost farming. Taking cognizance of this, market players are vying for an opportunity to expand their product portfolio across the region," infers an FMI analyst.

Request report sample in order to gain in-depth market insights at https://www.futuremarketinsights.com/reports/sample/rep-eg-704

Egypt below 30 HP Centrifugal Water Pumps Market- Key Takeaways

Submersible pumps gained significant traction due to their wide applications for industrial and domestic purposes. These pumps have captured greater than half of the overall market share.
Domestic application segment captured more than 40% of the overall market while industrial applications expanded the fastest at a CAGR of 5.5%.
Monobloc and submersible pumps with a capacity of 25-30 HP experienced widespread application, whereas mini-pumps segment of 1-2 HP captured half of the total market.
The Egypt below 30 HP centrifugal water pumps market expanded at a CAGR of 5.1% during the forecast period.

Egypt below 30 HP Centrifugal Water Pumps Market- Prominent Drivers

Increasing forays regarding discovery of additional water sources is driving the demand for below 30 HP centrifugal water pumps across Egypt. This is due to acute water shortages from existing sources due to an expanding population.
Growing environmental consciousness is prompting consumers to opt for cost-saving, energy efficient centrifugal water pumps for their daily activities.

Egypt below 30 HP Centrifugal Water Pumps Market- Key Constraints

Political instability and high price volatility have been constraining market expansion of below 30 HP centrifugal water pumps due to disruptions in production cycles.
Availability of substitutes in the form of foreign pumps is hindering growth prospects of regional market players.

Anticipated Impact of the Coronavirus Outbreak

With several end-use industries experiencing sluggish growth, the market for centrifugal water pumps has also taken a major hit due to the pandemic. Disrupted supply chains, insufficient inventory and a shortage of workforce in production units have contributed to reduced output. Additionally, the imposition of a nationwide lockdown has led to a reduction in economic activities, including agriculture, which has limited the uptake of below 30 HP centrifugal water pumps since the past three to four months. Fortunately, the impact is not as severe as it is on other industries. In fact, agricultural exports to other Arab countries has increased as a result of reduced imports from Europe, the Arab world's primary source of agricultural commodities. Furthermore, the country has been increasing cultivation of less water-intensive crops such as potatoes to keep food supplies running. Based on this trend, adoption of below 30 HP centrifugal water pumps shall increase during the course of the pandemic.

Explore the below 30 HP centrifugal water pumps report consisting of illustrative figures, data tables and the table of contents. You can also find detailed market segmentation on https://www.futuremarketinsights.com/askus/rep-eg-704

Competition Landscape

The Egyptian below 30 HP centrifugal water pumps market is highly consolidated, with regional players accounting for 70% of the overall market share. These market players are: KSB Pumps Ltd., Xylem Inc., Omega Egypt Co., Flowserve Corporation, Wilo SE, Calpeda S.p.A and Grundfos. These companies are largely focusing on innovations and technological advancements to offer a wider product portfolio and attract more customers. A key development in this respect is the introduction of photovoltaic powered centrifugal water pumps which not only increase performance but also aids in environmental protection. Partnerships and collaborations are also helping uplift market prospects for prominent players. For instance, Grundfos has proceeded with its acquisition of Eurowater in order to provide pioneering solutions to tackle global water challenges.

More Insights on the Below 30 HP Centrifugal Water Pump Market

FMI's below 30 HP centrifugal water pump market offers an unbiased analysis of the key dynamics influencing the growth trajectory of the market between 2015 and 2020. In order to paint an incisive picture, the market has been segmented into three categories: product type, application and capacity. By product type, the market has been categorized into monobloc pumps, mini pumps and submersible pumps. By application, the market is segmented as industrial, agriculture and domestic pumps. In terms of capacity, the market is divided into 0.5-30 HP pumps.

Explore FMI's Extensive Coverage on the Industrial Automation & Equipment Landscape

Pre Insulated Pipes Market: Investigate the key market dynamics, growth prospects and opportunities associated with the pre insulated pipes market across the forecast period 2020-2027 in FMI's recently concluded research report on the subject.

Protective Goggles Market: FMI's ongoing research study on the protective goggles markets offers readers a comprehensive insight on the business models, key strategies and market shares of prominent vendors in the landscape.

Emulsion Explosive Market: Danger and safety hazards project themselves as key concerns regarding the health and safety of underground miners. The use of emulsion explosives has played a pivotal role in addressing the same, projects FMI in its recent research report.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai, United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com

Market Report: https://www.futuremarketinsights.com/reports/egypt-centrifugal-water-pump-market
Press Release Source: https://www.futuremarketinsights.com/press-release/egypt-centrifugal-water-pump-market

SOURCE: Future Market Insights

ReleaseID: 595570

Broadening presence in the Industrial Internet of Things Market (IIoT)

LONDON, UK / ACCESSWIRE / June 29, 2020 / Dialog Semiconductor plc (XETRA:DLG), a leading provider of battery management, AC/DC power conversion, Wi-Fi, Bluetooth(R) low energy and Industrial integrated circuits (ICs), today announced that it has completed the acquisition of Adesto Technologies Corporation (Adesto) (NASDAQ:IOTS), a leading provider of innovative custom ICs and embedded systems for the IIoT market.

"This acquisition immediately adds scale to our Industrial IoT business, providing our expanded customer base with a broader portfolio of differentiated industrial products," said Jalal Bagherli, CEO of Dialog. "With the combined product portfolio, we now have the unique ability to connect and control from the factory automation line and building automation systems to the cloud. It is with great excitement that I welcome our new colleagues to Dialog following the completion of our acquisition of Adesto."

Dialog and the Dialog logo are trademarks of Dialog Semiconductor plc or its subsidiaries. All other product or service names are the property of their respective owners. (c) Copyright 2020 Dialog Semiconductor. All rights reserved.

Media Contact:

Mark Tyndall
SVP Corporate Development & Strategy
Dialog Semiconductor Inc.
Phone: +1 (408) 845 8520
mark.tyndall@diasemi.com
Web: www.dialog-semiconductor.com
Twitter: @DialogSemi

About Dialog Semiconductor

Dialog Semiconductor is a leading provider of ICs powering Internet of Things and Industry 4.0 applications. Dialog's solutions are integral to some of today's leading smartphones and facilitate increased performance and productivity on the go. From making smartphones more power efficient and shortening charging times, to enabling home appliances to be controlled from anywhere, to connecting the next generation of wearable devices, Dialog's decades of experience and world-class innovation help manufacturers get to what's next.

Dialog operates a fabless business model and is a socially responsible employer pursuing many programs to benefit its employees, community, other stakeholders and environment. Dialog is headquartered near London with a global sales, R&D and marketing organization. In 2019, it had approximately $1.42 billion in revenue and is consistently one of the fastest growing European public semiconductor companies. It currently has approximately 2,300 employees worldwide. The company is listed on the Frankfurt (FWB: DLG) stock exchange (Regulated Market, Prime Standard, ISIN GB0059822006)

Contact:
Jose Cano
Director, Investor Relations
jose.cano@diasemi.com
+44(0)1793756961

SOURCE: Dialog Semiconductor Plc.

ReleaseID: 595590

TEMPE, AZ / ACCESSWIRE / June 29, 2020 / Wrap Technologies, Inc. (the "Company" or "Wrap") (NASDAQ:WRTC), an innovator of modern policing solutions, today announced the Company has received a new follow-on order for 21,600 additional BolaWrap cartridges for the Indonesia National Police force.

Earlier this month, the Company reported the fulfillment of an initial order of devices and cartridges placed by the Company's distributor in Indonesia at the end of 2019. The Company's distributor recently secured a contract with the Indonesian National Police force following successful BolaWrap demonstrations across the country. The Company supplied the Indonesian National Police force with BolaWrap devices customized with the police force's logo and matching uniform colors.

"We are very pleased to see both new international orders and follow-on orders such as this one for a major police force," said Tom Smith, President at Wrap Technologies. "We believe this order reflects the Indonesian National Police force's acceptance of the BolaWrap as a viable solution to an age-old challenge in policing – safely detaining noncompliant subjects without injury."

The Indonesian National Police force consists of approximately 387,000 police officers, and they plan to use this new order of cartridges with previously purchased BolaWrap devices to begin training thousands of officers in their agency.

"Wrap has worked hard to develop a strong international distribution network representing 29 countries," said David Norris, CEO of Wrap Technologies. "BolaWrap devices are on the ground in 27 countries with distributors and agencies restarting demos and trainings following the COVID-19 lockdown. We believe BolaWraps' remote restraint responds to the social distancing question for law enforcement wanting to de-escalate without using pain compliance tools."

The Company expects to recognize revenue on this order in Q2 and Q3 of 2020.

Highlights from the BolaWrap demonstrations in Indonesia can be viewed here.

About Wrap Technologies (NASDAQ:WRTC)

Wrap Technologies is an innovator of modern policing solutions. The Company's BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the Company's Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the Company please visit www.wraptechnologies.com. Examples of recent media coverage are available as links under the "Media" tab of the website.

Trademark Information: BolaWrap and Wrap are trademarks of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company's overall business, total addressable market and expectations regarding future sales and expenses. Words such as "expect," "anticipate," "should," "believe," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "could," "intend," variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company's ability to successful implement training programs for the use of its products; the Company's ability to manufacture and produce product for its customers; the Company's ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company's product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company's ability to maintain and enhance its brand, as well as other risk factors included in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

WRAP TECHNOLOGIES CONTACT:

Paul M. Manley
VP – Investor Relations
612-834-1804
pmanley@wraptechnologies.com

SOURCE: Wrap Technologies

ReleaseID: 595589

TORONTO, CANADA / ACCESSWIRE / June 29, 2020 / First Growth Funds Limited (CSE:FGFL) ("FGFL or the "Company") is pleased to announce the listing of its ordinary shares ("Shares") on the Canadian Securities Exchange "CSE" on June 29, 2020 under the symbol CSE:FGFL.

The Company provides Advisory Services to companies and invests across a diversified portfolio of different asset classes, including equity and convertible note investments in large and small cap public listed and private companies. The Company also invests in technology companies involved in the development of blockchain solutions as well as direct investments in established and liquid Cryptocurrency (for example Bitcoin and Ethereum).

The current issued share capital of the Company is 77,798,218 fully paid ordinary shares. There are no outstanding options or warrants.

The Company's most recent transaction involved the acquisition of an unlisted technology company for a modest $940 that was subsequently sold to an ASX listed company for $900,000 in shares and then subsequently exited with $1.4M in cash. The two transactions were completed within last 12 months.

The Company has access to unique deal flow and can invest across multiple asset classes, geography and investment stages. The Company also provides Advisory services earning retainer fees and transaction fees for supporting its unlisted and listed investments.

First Growth Funds Limited is based in Australia but invests globally with a growing portfolio of listed and unlisted investments in North America. The Company has a strong balance sheet with over $10M in cash and investments.

For further information please visit the company's corporate website at www.firstgrowthfunds.com or the Company's profile at www.sedar.com where its final long form prospectus dated June 10, 2020 is available for review.

Contact:
Mark Pryn
Phone: +61.386206400
Email: cosec@firstgrowthfunds.com

About First Growth Funds Limited

First Growth Funds Limited invests across a broad range of asset classes including listed equities, private equity, blockchain and digital assets. The company also operates an advisory business providing corporate advisory, capital raising and capital markets support to its portfolio.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

SOURCE: First Growth Funds Limited

ReleaseID: 595522

DORTMUND, GERMANY / ACCESSWIRE / June 29, 2020 / The Covid-19 pandemic, with its ongoing restrictions on public life and the associated significant effects on both the global economy and Borussia Dortmund's operating business, has caused and is still causing considerable uncertainty. The company had therefore initially withdrawn its forecast for the entire 2019/2020 financial year from the market and made no new forecast (see our ad hoc announcement of March 16, 2020) and then – without a detailed earnings forecast – announced that the Management assumes that no positive consolidated annual result will be achieved for the entire 2019/2020 financial year (see our ad hoc announcement of May 8, 2020).

With completion of the 34th match day and the resulting termination of the Bundesliga season 2019/2020 – recently by means of special match operations "without spectators" – in the association's specified period of a season end before June 30th, the management of Borussia Dortmund decided today, based on the current findings, to give an outlook on key earnings figures for 2019/2020 financial year.

Borussia Dortmund group now expects an EBITDA of approx. EUR 62 million and a consolidated net loss of approx. EUR 45 million. This outlook is subject to value-adjusting facts until the completion of the preparation of the annual financial statements and the knowledge gained in the course of the audit of the consolidated financial statements for the 2019/2020 financial year after the balance sheet date as well as possible further transfer income.

The expected aforesaid key figures have to be understood as a direct impact of the Covid-19 pandemic, which has affected all Borussia Dortmund income and revenue sources. Borussia Dortmund has the largest stadium in Germany with a total capacity of 81,365 spectators and the second largest VIP hospitality areas. The special match operations "without spectators" therefore had a significant impact (see also our corporate news from March 9, 2020). In addition, reductions and / or refunds of advertising and VIP hospitality proceeds have been made. It is also important that the global transfer market came nearly to a complete standstill in the fourth quarter.

Due to the good earnings situation in the past financial years and in the period of the current financial year up to the start of the Covid-19 pandemic, due to a group equity of approx. EUR 355 million as of 30. June 2019 (corresponding to an equity ratio of approx. 71%) and thanks to the company's sustainable positioning, Borussia Dortmund is prepared to bear the expected losses.

The management continuously evaluates the situation around the ongoing Covid-19 pandemic and is now focusing on the development of new concepts and measures for the start of the new 2020/2021 season.

Dortmund, 29. June 2020

Borussia Dortmund GmbH & Co. KGaA
Borussia Dortmund Geschäftsführungs-GmbH

Contact:
Dr. Robin Steden
Inhouse Counsel / Investor Relations

SOURCE: Borussia Dortmund GmbH & Co. KGaA

ReleaseID: 595584

SAN DIEGO, CA / ACCESSWIRE / June 29, 2020 / snapIoT Inc., a San Diego-based company, announces Automated AI-powered IRB Packaging and UAT Reporting feature to assemble all patient-facing visual assets and expedite the submission process for IRB and ethics approvals. Traditionally, this time-consuming process of IRB and ethics packaging is prone to human error and performed manually at the end of app development stages.

snapClinical™'s AI-powered Automated Documentation Engine creates key patient facing documentation assets for IRB Package setup and submission as well as UAT Reporting. With one single click, an AI-powered automation engine will: execute the app, go through all screens and generate screenshots, traverse all protocol flows and gather forms data information and auto-generate the needed materials within a single report. Annotations can be documented and exported to various file formats for further editing and processing. Pharma and CRO companies now have a faster, more efficient, and reliable method to help launch digitally enabled clinical trials.

"We have worked very closely with an early stage User Group comprised of many of the Top 10 Pharmaceutical and CRO companies as well as several IRB and Ethics SME's to rapidly deploy this modern feature. Our Automated AI-powered IRB Packaging and UAT Reporting feature achieves the objectives of a better streamlined process to reduce time, costs and human error," said Isaac Eteminan, CEO of snapIoT.

About snapIoT

snapIoT, a San Diego-based company, is a market leader in de-centralized mClinical trial innovation. Their mClinical platform, snapClinical™, provides unlimited capabilities in developing and deploying patient-centric engagement solutions such as eConsent, eCOA, Telemedicine, and various other patient engagement solutions to support decentralized trials. snapClinical functions as both a SaaS/PaaS model to allow users to build self-service solutions on Android, iOS, and HTML5 via intuitive drag-and-drop platform, or as a full turnkey service. For more information, visit https://snapiot.com/ and follow snapIoT on LinkedIn.

Sales & Press Inquiries:

Mary Briggs
VP Delivery Excellence
mary@snapiot.com

SOURCE: snapIoT

ReleaseID: 595101